Kinase Profiling Inhibitor Database

This is a searchable database of specificities of 55684 commonly used signal transduction inhibitors. These results have been provided by the International Centre for Kinase profiling within the MRC Protein Phosphorylation Unit at the University of Dundee.

We strongly recommend undertaking kinase profiling of any kinase inhibitor to be used in a biological experiment. It is essential to have a good feel for the specificity of the kinase inhibitor you are working with in order to be able to properly interpret your data.

If you have additional kinase inhibitors that you would like the International Centre for Kinase profiling team to profile for you please contact us here for further details.

If you have any feedback or suggestions on how to improve this resource we welcome your input. Pass on your ideas to us here.

Inhibitor Brutto MW Action Reference Screen Conc % Activity Remaining
GSK461364   C27H28F3N5O2S 543.60 PLK1 T. R. Rheault (2010) Bioorg. Med. Chem. Lett. 20(15) 4587-92
K. A. Emmitte (2009) Bioorg. Med. Chem. Lett. 19(6) 1694-7

1.00 91
GSK461364   C27H28F3N5O2S 543.60 PLK1 T. R. Rheault (2010) Bioorg. Med. Chem. Lett. 20(15) 4587-92
K. A. Emmitte (2009) Bioorg. Med. Chem. Lett. 19(6) 1694-7

0.10 100
GW441756 hydrochloride   C17H13N3O • HCl 311.77 Trk A Wood E.R. (2004) Bioorg. Med. Chem. Lett. 14 953-957


1.00 62
GW843682X (GSK-PLK1 Compound 2)   C22H18F3N3O4S 477.46 PLK1 Emmitte K.A. (2009) Bioorganic and Medicinal Chemistry Letters 19 1018-1021


10.00 58
GW843682X (GSK-PLK1 Compound 2)   C22H18F3N3O4S 477.46 PLK1 Emmitte K.A. (2009) Bioorganic and Medicinal Chemistry Letters 19 1018-1021


0.10 102
GW843682X (GSK-PLK1 Compound 2)   C22H18F3N3O4S 477.46 PLK1 Emmitte K.A. (2009) Bioorganic and Medicinal Chemistry Letters 19 1018-1021


1.00 86
H-89, Dihydrochloride   C20H20BrN3O2S • 2HCl 519.30 PKA Leemhuis J. (2002) J. Pharmacol. Exp. Ther. 300 1000
Davies S.P. (2000) Biochem. J. 351 95
WO2003080649
10.00 101
H-89, Dihydrochloride   C20H20BrN3O2S • 2HCl 519.30 PKA Leemhuis J. (2002) J. Pharmacol. Exp. Ther. 300 1000
Davies S.P. (2000) Biochem. J. 351 95
WO2003080649
1.00 94
HG-10-102-01 LRRK2 Choi H.G. (2012) ACS Med. Chem. Lett.


10.00 86
HG-10-102-01 LRRK2 Choi H.G. (2012) ACS Med. Chem. Lett.


1.00 84